Medicxi Ventures Management

Latest statistics and disclosures from Medicxi Ventures Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are CNTA, NAMS, PHAT, AURA, and represent 100.00% of Medicxi Ventures Management's stock portfolio.
  • Reduced shares in these 2 stocks: Rapt Therapeutics (-$95M), NAMS (-$6.3M).
  • Sold out of its position in Rapt Therapeutics.
  • Medicxi Ventures Management was a net seller of stock by $-101M.
  • Medicxi Ventures Management has $982M in assets under management (AUM), dropping by 17.58%.
  • Central Index Key (CIK): 0001715579

Tip: Access up to 7 years of quarterly data

Positions held by Medicxi Ventures Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Medicxi Ventures Management

Medicxi Ventures Management holds 4 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Centessa Pharmaceuticals Sponsored Ads (CNTA) 80.8 $793M 20M 39.72
 View chart
Newamsterdam Pharma Company Ordinary Shares (NAMS) 8.7 $86M -6% 2.7M 32.01
 View chart
Phathom Pharmaceuticals (PHAT) 8.4 $83M 7.5M 11.11
 View chart
Aura Biosciences (AURA) 2.1 $20M 3.0M 6.69
 View chart

Past Filings by Medicxi Ventures Management

SEC 13F filings are viewable for Medicxi Ventures Management going back to 2019

View all past filings